title: American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma and Immunology Joint Task Force Report on omalizumab-associated anaphylaxis.
abstract: The American Academy of Allergy, Asthma & Immunology and the American College of Allergy, Asthma and Immunology Executive Committees formed the Omalizumab Joint Task Force with the purpose of reviewing the Genentech Xolair (omalizumab) clinical trials and postmarketing surveillance data on anaphylaxis and anaphylactoid reactions. Using the definition of anaphylaxis proposed at a 2005 multidisciplinary symposia, the Omalizumab Joint Task Force concluded that 35 patients had 41 episodes of anaphylaxis associated with Xolair (omalizumab) administration between June 1, 2003, and December 31, 2005. With 39,510 patients receiving Xolair (omalizumab) during the same period of time, this would correspond to an anaphylaxis-reporting rate of 0.09% of patients. Of those 36 events for which the time of reaction was known, 22 (61%) reactions occurred in the first 2 hours after one of the first 3 doses. Five (14%) of the events after the fourth or later doses occurred within 30 minutes. Considering the timing of these 36 events, an observation period of 2 hours for the first 3 injections and 30 minutes for subsequent injections would have captured 75% of the anaphylactic reactions. The OJTF report provides recommendations for physicians who prescribe Xolair (omalizumab) on (1) the suggested wait periods after administration and (2) patient education regarding anaphylaxis.
authors.affiliation: Department of Clinical Medicine, Nova Southeastern University College of Osteopathic Medicine, Davie, FL 33334, USA. lindaswolfcox@msn.com
authors.forename: Linda
authors.initials: L
authors.lastname: Cox
authors.forename: Thomas A E
authors.initials: TA
authors.lastname: Platts-Mills
authors.forename: Ira
authors.initials: I
authors.lastname: Finegold
authors.forename: Lawrence B
authors.initials: LB
authors.lastname: Schwartz
authors.forename: F Estelle R
authors.initials: FE
authors.lastname: Simons
authors.forename: Dana V
authors.initials: DV
authors.lastname: Wallace
mesh_terms: D000047:Academies and Institutes / Q000592:standards; D026683:Advisory Committees / Q000592:standards; D000486:Allergy and Immunology / Q000592:standards; D000707:Anaphylaxis / Q000276:immunology* / Q000517:prevention & control; D018926:Anti-Allergic Agents / Q000009:adverse effects*; D018927:Anti-Asthmatic Agents / Q000009:adverse effects*; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D001249:Asthma / Q000150:complications / Q000276:immunology / Q000628:therapy*; D006801:Humans; D000069444:Omalizumab; D014481:United States
chemical_list: D018926:Anti-Allergic Agents; D018927:Anti-Asthmatic Agents; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069444:Omalizumab